These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 34839932)

  • 1. Serum urate as a proposed surrogate outcome measure in gout trials: From the OMERACT working group.
    Morillon MB; Christensen R; Singh JA; Dalbeth N; Saag K; Taylor WJ; Neogi T; Kennedy MA; Pedersen BM; McCarthy GM; Shea B; Diaz-Torne C; Tedeschi SK; Grainger R; Abhishek A; Gaffo A; Nielsen SM; Noerup A; Simon LS; Lassere M; Tugwell P; Stamp LK; Gout Working Group FTO
    Semin Arthritis Rheum; 2021 Dec; 51(6):1378-1385. PubMed ID: 34839932
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Using serum urate as a validated surrogate end point for flares in patients with gout: protocol for a systematic review and meta-regression analysis.
    Morillon MB; Stamp L; Taylor W; Fransen J; Dalbeth N; Singh JA; Christensen R; Lassere M
    BMJ Open; 2016 Sep; 6(9):e012026. PubMed ID: 27650765
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum urate as surrogate endpoint for flares in people with gout: A systematic review and meta-regression analysis.
    Stamp L; Morillon MB; Taylor WJ; Dalbeth N; Singh JA; Lassere M; Christensen R
    Semin Arthritis Rheum; 2018 Oct; 48(2):293-301. PubMed ID: 29566967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of efficacy and safety of urate-lowering therapies for hyperuricemic patients with gout: a meta-analysis of randomized, controlled trials.
    Fan M; Liu J; Zhao B; Wu X; Li X; Gu J; Schlesinger N
    Clin Rheumatol; 2021 Feb; 40(2):683-692. PubMed ID: 32654080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum urate as a soluble biomarker in chronic gout-evidence that serum urate fulfills the OMERACT validation criteria for soluble biomarkers.
    Stamp LK; Zhu X; Dalbeth N; Jordan S; Edwards NL; Taylor W
    Semin Arthritis Rheum; 2011 Jun; 40(6):483-500. PubMed ID: 21056459
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum urate in chronic gout--will it be the first validated soluble biomarker in rheumatology?
    Stamp LK; Khanna PP; Dalbeth N; Boers M; Maksymowych WP; Schumacher HR; Becker MA; MacDonald PA; Edwards NL; Singh JA; Simon LS; McQueen FM; Neogi T; Gaffo AL; Strand V; Taylor WJ
    J Rheumatol; 2011 Jul; 38(7):1462-6. PubMed ID: 21724717
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intensive Serum Urate Lowering With Oral Urate-Lowering Therapy for Erosive Gout: A Randomized Double-Blind Controlled Trial.
    Dalbeth N; Doyle AJ; Billington K; Gamble GD; Tan P; Latto K; Parshu Ram T; Narang R; Murdoch R; Bursill D; Mihov B; Stamp LK; Horne A
    Arthritis Rheumatol; 2022 Jun; 74(6):1059-1069. PubMed ID: 34927391
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Change in serum urate level with urate-lowering therapy initiation associates in the immediate term with patient-reported outcomes in people with gout.
    Topless R; Noorbaloochi S; Merriman TR; Singh JA
    Semin Arthritis Rheum; 2022 Oct; 56():152057. PubMed ID: 35835008
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lack of effect of tart cherry concentrate dose on serum urate in people with gout.
    Stamp LK; Chapman P; Frampton C; Duffull SB; Drake J; Zhang Y; Neogi T
    Rheumatology (Oxford); 2020 Sep; 59(9):2374-2380. PubMed ID: 31891407
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predicting Response or Non-response to Urate-Lowering Therapy in Patients with Gout.
    Graham GG; Stocker SL; Kannangara DRW; Day RO
    Curr Rheumatol Rep; 2018 Jun; 20(8):47. PubMed ID: 29931553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pegloticase for treating refractory chronic gout.
    George RL; Sundy JS
    Drugs Today (Barc); 2012 Jul; 48(7):441-9. PubMed ID: 22844655
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prescription and dosing of urate-lowering therapy, rather than patient behaviours, are the key modifiable factors associated with targeting serum urate in gout.
    Dalbeth N; House ME; Horne A; Petrie KJ; McQueen FM; Taylor WJ
    BMC Musculoskelet Disord; 2012 Sep; 13():174. PubMed ID: 22978848
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcome reporting in randomized trials in gout: A systematic scoping review from the OMERACT gout working group assessing the uptake of the core outcome set.
    Morillon MB; Nørup A; Singh JA; Dalbeth N; Taylor WJ; Kennedy MA; Pedersen BM; Grainger R; Tugwell P; Perez-Ruiz F; Diaz-Torne C; Edwards NL; Shea B; Ellingsen TJ; Christensen R; Stamp LK;
    Semin Arthritis Rheum; 2023 Jun; 60():152191. PubMed ID: 36963128
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fluctuation and change of serum urate levels and flares in gout: results from the NOR-Gout study.
    Uhlig T; Karoliussen LF; Sexton J; Kvien TK; Haavardsholm EA; Perez-Ruiz F; Hammer HB
    Clin Rheumatol; 2022 Dec; 41(12):3817-3823. PubMed ID: 36316609
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A nurse-led, rheumatologist-assisted telemedicine intervention for dose escalation of urate-lowering therapy in gout.
    Phang KF; Santosa A; Low BPL; Tan PSH; Khong ZW; Lim AYN; Teng GG; Tay SH
    Int J Rheum Dis; 2020 Aug; 23(9):1136-1144. PubMed ID: 32483906
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved joint and patient-reported health assessments with pegloticase plus methotrexate co-therapy in patients with uncontrolled gout: 12-month exploratory outcomes of the MIRROR open-label trial.
    Botson JK; Obermeyer K; LaMoreaux B; Zhao L; Weinblatt ME; Peterson J
    Arthritis Res Ther; 2022 Dec; 24(1):281. PubMed ID: 36575505
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lowering Serum Urate With Urate-Lowering Therapy to Target and Incident Fracture Among People With Gout.
    Wei J; Choi HK; Dalbeth N; Lane NE; Wu J; Lyu H; Zeng C; Lei G; Zhang Y
    Arthritis Rheumatol; 2023 Aug; 75(8):1456-1465. PubMed ID: 36940260
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Significance of the initiation time of urate-lowering therapy in gout patients: A retrospective research.
    Feng X; Li Y; Gao W
    Joint Bone Spine; 2015 Dec; 82(6):428-31. PubMed ID: 26456042
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Concurrent validity of provisional remission criteria for gout: a dual-energy CT study.
    Dalbeth N; Frampton C; Fung M; Baumgartner S; Nicolaou S; Choi HK
    Arthritis Res Ther; 2019 Jun; 21(1):150. PubMed ID: 31227018
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect modification by contextual factors of urate-lowering therapy on serum urate in people with gout: A systematic review with meta-regression analysis.
    Kampe RT; Nielsen SM; Hotea I; van Durme C; Christensen R; Boonen A
    Semin Arthritis Rheum; 2022 Oct; 56():152049. PubMed ID: 35728446
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.